Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Novavax Q4 GAAP EPS $(1.44) May Not Be Comparable To $(0.45) Estimate, Sales $291.34M Miss $321.97M Estimate

Author: Benzinga Newsdesk | February 28, 2024 09:02am
Novavax (NASDAQ:NVAX) reported quarterly losses of $(1.44) per share which missed the analyst consensus estimate of $(0.45) by 220 percent. This is a 36.84 percent increase over losses of $(2.28) per share from the same period last year. The company reported quarterly sales of $291.34 million which missed the analyst consensus estimate of $321.97 million by 9.51 percent. This is a 18.48 percent decrease over sales of $357.40 million the same period last year.

Posted In: NVAX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist